Teresa Imperiale-Westerfield
Family · Melbourne, FLNPI 1821147455
Payments from drug & device makers
Across 368 payments — averaging $25.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AbbVie$832
- Mallinckrodt Hospital Products Inc.$717
- Pfizer$663
- AstraZeneca$656
- Radius Health, Inc.$586
- plus $3K from 29 others
What the payments were for
- Consulting fees$4205%
- Food & beverage$8,71194%
- Education$1732%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 73 | $2,384 |
| AbbVie | 34 | $832 |
| Mallinckrodt Hospital Products Inc. | 36 | $717 |
| Pfizer | 55 | $663 |
| AstraZeneca(2 entities) | 8 | $656 |
| Radius Health, Inc. | 31 | $586 |
| GSK | 23 | $524 |
| UCB, Inc. | 23 | $425 |
| Beigene USA, Inc. | 11 | $417 |
| Lilly USA, LLC | 16 | $414 |
| Aurinia Pharma U.S., Inc. | 13 | $372 |
| Johnson & Johnson | 8 | $274 |
| Daiichi Sankyo Inc. | 6 | $145 |
| Boehringer Ingelheim | 3 | $132 |
| Novo Nordisk | 1 | $119 |
| Biohaven Pharmaceuticals, Inc. | 1 | $100 |
| E.r. Squibb & Sons, L.L.C. | 5 | $76 |
| Stimwave Technologies Incorporated | 1 | $59 |
| Almatica Pharma LLC | 2 | $41 |
| Organon | 2 | $38 |
| Bristol Myers Squibb | 1 | $36 |
| Novartis | 2 | $36 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Agios Pharmaceuticals, Inc. | 1 | $24 |
| Eisai Inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Biocon Biologics Inc | 1 | $22 |
| Global Blood Therapeutics, Inc. | 1 | $22 |
| Merck | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Dendreon Pharmaceuticals LLC | 1 | $19 |
| Menarini Silicon Biosystems, Inc. | 1 | $17 |
| Sobi, Inc | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Recordati_rare_diseases_inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,304 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 62 | $522,072 |
| Enbrel SureclickEtanercept | 35 | $265,511 |
| RinvoqUpadacitinib | 25 | $176,525 |
| Orencia ClickjectAbatacept | 25 | $151,933 |
| XeljanzTofacitinib Citrate | 23 | $149,724 |
| Xeljanz XrTofacitinib Citrate | 20 | $144,309 |
| OtezlaApremilast | 21 | $110,188 |
| TymlosAbaloparatide | 21 | $55,049 |
| SavellaMilnacipran Hcl | 25 | $24,209 |
| LyricaPregabalin | 58 | $19,642 |
| Hydroxychloroquine Sulfate | 300 | $12,601 |
| Leflunomide | 88 | $4,916 |
| Risedronate Sodium DrRisedronate Sodium | 18 | $4,331 |
| MethotrexateMethotrexate Sodium | 162 | $3,855 |
| Duloxetine Hcl | 122 | $2,932 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Savella | $832 | $200,73450 claims |
| PfizerXeljanz, Lyrica | $663 | $169,36681 claims |
| AmgenOtezla | $2,384 | $110,18821 claims |
| Radius Health, Inc.Tymlos | $586 | $55,04921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Melbourne
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.